“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Associated equity: OpGen
OpGen is primarily a lab diagnostic manufacturer focused on identifying and treating bacterial infections. It has the technology to detect pathogens and predict resistance and through the dual platform offering of the AMR Gene Panel and Unyvero, it can provide diagnostic results in hours instead of days.
OpGen — 5 videos in collection
This interactive webinar with OpGen’s CEO Oliver Schacht, CFO Tim Dec and COO Johannes Bacher highlights recent progress in the fight against Antimicrobial Resistance. The presentation includes updates on R&D progress, FDA and NMPA regulatory reviews and pending approvals, upcoming clinical trials, and business development and partnering opportunities. The speakers also comment on key corporate development topics around the shareholder support required to authorise new shares for future strategic development and financing.
Get access to the very latest content matched to your personal investment style.
